Organization: Alnylam Pharmaceuticals
Executive: Susan Geller
Position: Associate Director, HR Systems and Operations
Date: January 15, 2018
WinterWyman Executive Search has placed Susan Geller as Associate Director, HR Systems and Operations at Alnylam Pharmaceuticals, the leading RNAi therapeutics company. WinterWyman Executive Search's Senior Vice President and Partner Beverly Morgan led the search.
As the Associate Director, HR Systems and Operations, Geller will work with other senior HR executives to lead the newly created HR PMO (Project Management Office) to identify, prioritize and manage key HR projects, including initiation, planning, execution, monitoring, control and closure. Additionally, Geller will lead the business process design and redesign of active work-streams and technologies. She will work with internal partners to create project plans, including deliverables, activities, timelines and budgets and manage collaboration throughout Alnylam. Geller also will partner with HR leadership and other HR functional areas to identify, recommend and implement opportunities for process improvement in alignment with HR strategy and initiatives.
Prior to joining Alnylam, Geller was the Senior Manager, HR IT, Core Systems for The Boston Consulting Group where she had previously served as their Project Manager, HR IT, Talent Acquisition. Previously, she was the Human Capital Project Manager, Senior Managing Consultant, Service Area Manager for IBM Corporation (NYSE: IBM). Earlier in her career, Geller held roles as a Human Capital Management Senior Consultant and Project Manager for Renaissance Worldwide / The Hunter Group and a City HR Director and HRIS Project Manager for LSG Sky Chefs.
Alnylam (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam's pipeline of investigational RNAi therapeutics is focused in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. By the end of 2020, Alnylam expects to achieve a company profile with three marketed products, 10 RNAi therapeutic clinical programs - including four in late stages of development - across its three STArs.
ABOUT WINTERWYMAN EXECUTIVE SEARCH
WinterWyman Executive Search is a leading boutique retained search firm and authority on executive hiring for venture-backed, growth stage and large public companies. Learn more at wwexecutivesearch.com.